JPRN-jRCT2080221994
Unknown
Phase 2
An Exploratory Study for AD-810N in Patients with Parkinsonism in Dementia with Lewy Bodies (Phase 2 study)
Dainippon Sumitomo Pharma Co., Ltd.0 sites150 target enrollmentStarted: December 28, 2012Last updated:
Overview
- Phase
- Phase 2
- Enrollment
- 150
Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- >= 20age old to <= 84age old (—)
- Sex
- All
Inclusion Criteria
- •Patients met the diagnostic criteria of probable DLB
- •\-Outpatients
- •\-Patients taking L\-DOPADCI in succession more than 12 weeks
Exclusion Criteria
- •\-Patients with parkinsonism excepting Dementia with Lewy Bodies
- •\-Patients with Parkinson's disease with dementia
- •\-Epileptic patients
- •\-Patients treated with zonisamide
Investigators
Similar Trials
Unknown
Phase 3
Confirmatory Study for AD-810N in Patients with Parkinsonism in Dementia with Lewy Bodies.JPRN-jRCT2080222787Sumitomo Dainippon Pharma Co., Ltd.300
Unknown
Phase 3
A double-blind confirmatory study for AD-810N (zonisamide) in patients with Parkinson's disease (Phase III)Parkinson's diseaseJPRN-jRCT2080221162Dainippon Sumitomo Pharma Co., Ltd.360
Active, not recruiting
Phase 1
A Phase 1 and 2 Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of AZD8233 Following a Multiple Subcutaneous Dose Administration in Japanese Participants With DyslipidemiaDyslipidemiaJPRN-jRCT2051210041Hibi Kazushige91
Completed
Phase 1
An Exploratory Study of ADR-001 in Patients with Severe Pneumonia caused by SARS-CoV-2 infection (COVID-19)Patients with Severe Pneumonia caused by SARS-CoV-2 infectionJPRN-jRCT1080225320ROHTO PHARMACEUTICAL CO., LTD.6
Recruiting
Phase 2
A Phase 2 Study of ADR-001 in Patients with Severe Pneumonia caused by SARS-CoV-2 infectioPatients with Severe Pneumonia caused by SARS-CoV-2 infectionJPRN-jRCT2053210023Okawa Sumito20